J. Uzokov1, A. Alyavi1, S. Azizov1, B. Alyavi1 (1Tashkent UZ)
Background and Aims:
Aim of the study was to investigate the influence of combined lipid lowering therapy with rosuvastatin and ezetimibe on lipid profile, inflammatory state and pro-inflammatory cytokines in dyslipidemic patients with coronary heart disease (CHD) and metabolic syndrome (MS).
Material and Methods:
128 patients with CHD and MS were randomly divided into two groups per 64. First group was provided rosuvastatin (10 mg) + ezetimibe (10 mg) and the second group (control) was provided only rosuvastatin (10 mg). Plasma lipids, inflammatory state (hs-CRP), and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) were measured at baseline and in 12 weeks.
The level of TC, LDL-C was decreased significantly in combination group than controls (P<0.05), however there was not significant difference between 2 groups on HDL-C (P>0.05). Hs-CRP was decreased by 38% in the first group (P=0.003) vs. 31% in control group (P=0.005) from baseline, however there was no obvious changes between 2 groups. Even though, pro-inflammatory cytokines: TNF-α (from 1.42±0.98 to 0.87±0.18 in 12 weeks, P=0.018), IL-6 (from 7.8 pg/mL to 4.1 pg/mL, P=0.012), IL-1β (from 28.4±19.5 pg/ml to 17.5±15.8 pg/ml, P=0.010) in the combination group vs. TNF-α (from 1.48±1.12 to 1.12±0.25, P=0.047), IL-6 (from 8.0 pg/mL to 5.9 pg/mL, P=0.037), IL-1β (from 29.6±20.6 pg/ml to 20.6±17.4 pg/ml, P=0.040) significantly decreased in both groups from baseline however, there were statistically significant changes observed only in the first group (P<0.05) when compared two groups.
Therapy with rosuvastatin and ezitemibe is superior than rosuvastatin alone to improve TC, LDL-C and pro-inflammatory cytokines in patients with CHD and MS.